KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Evolent Health (EVH) EBIT (2016 - 2025)

Historic EBIT for Evolent Health (EVH) over the last 11 years, with Q3 2025 value amounting to $886000.0.

  • Evolent Health's EBIT rose 10544.63% to $886000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.5 million, marking a year-over-year increase of 5258.22%. This contributed to the annual value of -$40.5 million for FY2024, which is 4314.78% up from last year.
  • Latest data reveals that Evolent Health reported EBIT of $886000.0 as of Q3 2025, which was up 10544.63% from -$1.2 million recorded in Q2 2025.
  • In the past 5 years, Evolent Health's EBIT registered a high of $13.0 million during Q3 2022, and its lowest value of -$21.6 million during Q2 2023.
  • Over the past 5 years, Evolent Health's median EBIT value was -$7.7 million (recorded in 2021), while the average stood at -$8.0 million.
  • As far as peak fluctuations go, Evolent Health's EBIT surged by 29679.38% in 2022, and later crashed by 103684.77% in 2023.
  • Quarter analysis of 5 years shows Evolent Health's EBIT stood at -$12.2 million in 2021, then soared by 84.62% to -$1.9 million in 2022, then plummeted by 1036.85% to -$21.3 million in 2023, then rose by 12.9% to -$18.6 million in 2024, then surged by 104.76% to $886000.0 in 2025.
  • Its last three reported values are $886000.0 in Q3 2025, -$1.2 million for Q2 2025, and -$1.6 million during Q1 2025.